News and Trends 20 Nov 2023
M&As: what’s up with the ADC buying spree?
Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]